Elisabetta Bonzano MD, PhD路 @to_be_elizabeth 路 X路路 1 day agoScore70
Body 路 original
馃搶 Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
@KalinskyKevin
#ESMO26 馃嚜馃嚫 @OncoAlert #OncoAlertAF
108 views 路 4 likes 路 3 reposts 路 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Elisabetta Bonzano MD, PhD 路 x.com